PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-12.41%
Negative revenue growth while TRVN stands at 1.69%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-12.41%
Negative gross profit growth while TRVN is at 77.50%. Joel Greenblatt would examine cost competitiveness or demand decline.
-27.47%
Negative EBIT growth while TRVN is at 1.52%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-27.47%
Negative operating income growth while TRVN is at 1.52%. Joel Greenblatt would press for urgent turnaround measures.
-27.92%
Negative net income growth while TRVN stands at 1.79%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-20.00%
Negative EPS growth while TRVN is at 2.79%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-20.00%
Negative diluted EPS growth while TRVN is at 2.79%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
6.47%
Share count expansion well above TRVN's 0.70%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
6.47%
Diluted share count expanding well above TRVN's 0.70%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-21.90%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-21.77%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2645.13%
Negative 10Y OCF/share CAGR while TRVN stands at 71.49%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
92.60%
5Y OCF/share CAGR is similar to TRVN's 84.65%. Walter Schloss might see parallel cost profiles or expansions producing comparable cash flow.
85.56%
Positive 3Y OCF/share CAGR while TRVN is negative. John Neff might see a big short-term edge in operational efficiency.
-3055.33%
Negative 10Y net income/share CAGR while TRVN is at 71.74%. Joel Greenblatt sees a major red flag in long-term profit erosion.
92.82%
5Y net income/share CAGR similar to TRVN's 85.38%. Walter Schloss might see both on parallel mid-term trajectories.
82.14%
Positive short-term CAGR while TRVN is negative. John Neff would see a clear advantage in near-term profit trajectory.
1796.75%
Equity/share CAGR of 1796.75% while TRVN is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
-58.41%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
18.52%
Positive short-term equity growth while TRVN is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.03%
Positive asset growth while TRVN is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
-6.32%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-20.42%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
29.66%
We increase R&D while TRVN cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
16.61%
We expand SG&A while TRVN cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.